However, studies suggest that the mutually antagonizing players FOXOs and c-Myc can work together under the control of epigenetic factors, to form an MLL2/FOXO/c-Myc axis that is activated by lapatinib, a drug used to treat HER2+ breast cancer, thereby reducing sensitivity to the drug [143]. Here, ERBB2 is linked to breast carcinoma.